Colchicine in Stable Coronary Artery Disease

Aernoud T.L. Fiolet*, Stefan M. Nidorf, Arend Mosterd, Jan H. Cornel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Purpose: Disease management of stable coronary artery disease consists of controlling hemostasis and lipid regulation. No treatment strategies preventing plaque erosion or rupture are yet available. Cholesterol crystal–induced inflammation leading to plaque destabilization is believed to be an important factor contributing to plaque instability and might well be amenable to treatment with anti-inflammatory drugs. Colchicine has anti-inflammatory properties with the potential to address both the direct and indirect inflammatory mechanisms in the plaque. Methods: A literature search was performed in MEDLINE (PubMed), EMBASE, and the Cochrane Central Register of Controlled Trials, as well as in the clinical trial registries, to identify finished and ongoing clinical studies on colchicine in stable coronary artery disease. Findings: Preclinical findings of colchicine in stable coronary artery disease have shown protective effects on surrogate outcomes, such as myocardial infarction size and postangioplasty restenosis. Retrospective cohort studies in patients with gout report a lower incidence of combined cardiovascular outcomes in those treated with colchicine. Thus far, one prospective, randomized clinical trial has provided evidence on a possible protective effect of colchicine in stable coronary artery disease. Meta-analysis of trials of colchicine in multiple cardiovascular diseases revealed a decrease in myocardial infarction with varying levels of evidence. Currently, 5 major clinical trials involving >10,000 patients are recruiting patients, all focusing on major cardiovascular outcomes. Implications: The body and quality of evidence regarding the efficacy of colchicine for secondary prevention of stable and acute phases of coronary artery disease will be greatly expanded in the upcoming years, providing less biased and more accurate effect estimates. If colchicine's anti-inflammatory characteristics translate to improved event-free cardiovascular survival, this relatively safe, low-cost, and well-known drug may become the third pillar (next to lipid regulation and platelet inhibition) in the medical management of stable coronary artery disease.

Original languageEnglish
Pages (from-to)30-40
Number of pages11
JournalClinical Therapeutics
Volume41
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • anti-inflammatory drugs
  • clinical trials
  • colchicine
  • coronary artery disease
  • drug rediscovery
  • myocardial infarction
  • Plaque, Atherosclerotic/drug therapy
  • Coronary Artery Disease/drug therapy
  • Humans
  • Gout/drug therapy
  • Secondary Prevention
  • Randomized Controlled Trials as Topic
  • Anti-Inflammatory Agents/therapeutic use
  • Colchicine/therapeutic use
  • Myocardial Infarction/drug therapy
  • Inflammation/drug therapy

Fingerprint

Dive into the research topics of 'Colchicine in Stable Coronary Artery Disease'. Together they form a unique fingerprint.

Cite this